EMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Eastman Chemical Co (EMN) is not a strong buy for a beginner investor with a long-term focus at this time. The stock is facing cyclical and structural challenges, as reflected in its weak financial performance, declining price trend, and mixed analyst sentiment. While hedge funds are buying, and the stock is seen as a high dividend-yielding option, the lack of significant positive catalysts and weak technical indicators suggest holding off on investment until clearer signs of recovery emerge.
The MACD is negative and expanding (-0.808), indicating bearish momentum. RSI is at 35.131, which is neutral but leaning toward oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 74.964), with resistance far above at R1: 82.13. Overall, the technical indicators suggest a weak price trend.
Hedge funds are significantly increasing their holdings, with a 626.44% increase in buying over the last quarter. The stock is also being highlighted as a high dividend-yielding option during market turbulence.
The company's Q4 2025 financials show significant declines in revenue (-12.12% YoY), net income (-68.18% YoY), EPS (-67.49% YoY), and gross margin (-30.59% YoY). Analysts have mixed views, with several downgrades and concerns about cyclical and structural challenges. Technical indicators are weak, and the stock has a projected negative trend in the short term (-1.98% in the next week, -8.02% in the next month).
In Q4 2025, Eastman Chemical reported a sharp decline in financial performance, with revenue dropping to $1.973 billion (-12.12% YoY), net income falling to $105 million (-68.18% YoY), and EPS decreasing to $0.92 (-67.49% YoY). Gross margin also dropped significantly to 17.13% (-30.59% YoY). These figures highlight ongoing cyclical softness and operational challenges.
Analyst sentiment is mixed. Recent upgrades include price targets raised to $75-$79 by Evercore ISI, RBC Capital, Citi, and BofA, with Buy or Neutral ratings. However, concerns about weak demand, cyclical downturns, and limited organic growth opportunities persist. RBC and Fermium Research maintain cautious views, citing delayed recovery and ongoing softness in demand.
